Canada: Food, Drugs, Healthcare, Life Sciences

The Canadian Food Inspection Agency (CFIA) published proposed amendments to the Plant Breeders' Rights Regulations (PBR Regulations), initiating a public consultation period that will close on October 18, 2025.

September 21, 2025, marked the eighth anniversary of the significant amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations).

On September 24, 2025, the Supreme Court of Canada (SCC) granted a temporary stay of the Canadian Food Inspection Agency's (CFIA) Notice to Dispose, which ordered the culling of approximately 400 ostriches...

The Canadian Food Inspection Agency (CFIA) published proposed amendments to the Plant Breeders' Rights Regulations (PBR Regulations), initiating a public consultation period that will close on October 18, 2025.

As we previously reported, Health Canada completed consultation on its draft guidance for determining medical device application type.

In July 2025, the federal government issued a directive to federal regulators to examine their internal process and issue a report on where efficiencies can be achieved.

Regulated professions in Saskatchewan are governed by different legislation which sets out requirements related to membership, obligations of members and the regulator, and governance, among other things.

When a woman is in labour, one of the most important tools doctors and nurses rely on is fetal heart monitoring. This monitoring helps the healthcare team understand how a baby is handling labour...

In recent headlines, a Regina physician was found guilty by the College of Physicians and Surgeons of Saskatchewan (CPSS) of unprofessional misconduct for engaging in sexual impropriety...

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.